Therapy Areas: Hereditary Disorders
FDA Approves Kalydeco as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene
20 August 2018 - - The US Food and Drug Administration approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis ages 12 to
Login
Username:

Password:


Related Headlines